AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04386070
Drug: RESP301
RxNorm normalized name: RESP301
DrugBank: RESP301 (DB16497)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RESP301 is a formulation consisting of three agents already used in clinical practice: mannitol, sodium nitrite and citric acid. Delivered by a vibrating mesh nebuliser three times per day (TID) (at least 4 hours apart), for 7 days. Each dose of RESP301 is a 6ml admixture of 150mM NaNO2, 50mM mannitol and 100mM citric acid, buffered at pH 5.4.
Trial: NCT06411639
Drug: ianalumab
RxNorm normalized name: Ianalumab
DrugBank: Ianalumab (DB16666)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ianalumab will be provided in a pre-filled Syringe (PFS) of 150 mg/1 mL for s.c. administration. Two injections of 1mL each will be administered monthly.
Trial: NCT05770219
Drug: TAK-755
RxNorm normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-755 as IV injection at dose calculated based on the participant's body weight as measured at each dosing visit. For most participants, the final volume of infusion will be between 5 and 14 mL.
Trial: NCT05172934
Drug: intra-arterial tenecteplase
RxNorm normalized name: methotrexate
DrugBank: Tenecteplase (DB00031)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: intra-arterial drug administered after mechanical thrombectomy
Trial: NCT06117891
Drug: Atezolizumab
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Atezolizumab combined with Bevacizumab, immune checkpoint inhibitors combination.
Trial: NCT06117891
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Atezolizumab combined with Bevacizumab, immune checkpoint inhibitors combination.
Trial: NCT06117891
Drug: Durvalumab
RxNorm normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Durvalumab combined with Tremelimumab, another immuno-oncology (IO) checkpoint inhibitors combination.
Trial: NCT06117891
Drug: Tremelimumab,
DrugBank: Tremelimumab (DB11771)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Durvalumab combined with Tremelimumab, another immuno-oncology (IO) checkpoint inhibitors combination.
Trial: NCT05276973
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT05276973
Drug: Ipatasertib
RxNorm normalized name: Ipatasertib
DrugBank: Ipatasertib (DB11743)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT05276973
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given IV
Trial: NCT04566991
Drug: Deferoxamine
RxNorm normalized name: Deferoxamine
DrugBank: Deferoxamine (DB00746)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: There will be 3 doses given to the patients days 1-3. Dose will be given intravenous with a fixed rate of 7.5 milligram per kilogram per hour (mg/kg/hr). The second dose will be given 24 hours after the first dose, and the third dose will be given 48 hours after the initial dose.~Patients will be randomized to 32 mg/kg or 48 mg/kg of Deferoxamine.
Trial: NCT05969795
Drug: Progesterone 100 Mg Vaginal Insert
RxNorm normalized name: progesterone 100 MG Vaginal Insert
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: On day of ET procedure, to administer 200 mg of vaginal progesterone and increase to 300 mg/day from the day after the ET onwards until the pregnancy test. In case of an implantation, vaginal P4 will be continued until 7 weeks of pregnancy
Trial: NCT04395508
Drug: Pertuzumab and Trastuzumab Fixed-Dose Combination for Subcutaneous Administration (PH FDC SC)
RxNorm normalized name: hyaluronidase / pertuzumab / trastuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: PH FDC SC is given as a fixed dose (i.e. non-weight based) subcutaneous injection. Two dosage configurations of PH FDC SC may be administered in the study: a 15-millilitre (mL) loading dose consisting of 1200 milligrams (mg) pertuzumab and 600 mg trastuzumab and a 10-mL maintenance dose consisting of 600 mg pertuzumab and 600 mg trastuzumab. Participants who have had ≥6 weeks since their last P+H IV, PH FDC SC, or are receiving trastuzumab SC treatment must receive a loading dose before continuing with maintenance doses for subsequent administrations. Note that participants receiving trastuzumab SC only (i.e. without pertuzumab) must receive a loading dose regardless of time since last treatment.
Trial: NCT06347159
Drug: EDG-7500
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid suspension formulation of EDG-7500
Trial: NCT06347159
Drug: EDG-7500
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solid oral formulation of EDG-7500
Trial: NCT06220643
Drug: triamcinolone acetonide plus lidocaine
RxNorm normalized name: Triamcinolone Acetonide
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40mg triamcinolone acetonide 1cc plus 2cc lidocaine (1%)
Trial: NCT04266275
Drug: Curcumin C3 Complex
DrugBank: Cumin (DB10864)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcumin (Curcumin C3 Complex prepared by Sabinsa Corporation), a constituent of the spice turmeric, is considered to be a low-toxicity, dietary-derived agent with chemopreventative and therapeutic benefits.~Study participants will be instructed to insert four 500 mg (2000 mg total) curcumin capsules once a week (excluding days when they are on their menses) for 20 weeks. Participants will insert capsules using the vaginal applicator while lying on their back with their knees bent. Participants will be instructed to gently insert the capsules into the vagina as far as they will go comfortably, similar to a tampon insertion or other common intravaginal drugs.~Cervical cytology and HPV testing will be performed at baseline and 6 months after the baseline visit. If cervical cytology or HPV testing is abnormal at 6 months, a colposcopy with biopsies will be performed. All samples will be used to analyze for the study outcomes.
Trial: NCT06160791
Drug: Ruxolitinib
RxNorm normalized name: Ruxolitinib
DrugBank: Ruxolitinib (DB08877)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered Orally (PO)
Trial: NCT06160791
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered IV
Trial: NCT06160791
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered PO or IV
Trial: NCT06401603
Drug: Decitabine
RxNorm normalized name: Decitabine
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given by IV
Trial: NCT06401603
Drug: Listaftoclax
RxNorm normalized name: Lisaftoclax
DrugBank: Lisaftoclax (DB18054)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given by PO
Trial: NCT06401603
Drug: Olverembatinib
RxNorm normalized name: Olverembatinib
DrugBank: HQP1351 (DB16185)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given by PO
Trial: NCT05205850
Drug: RC118-ADC
RxNorm normalized name: dimethicone
DrugBank: RC118 (DB18428)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: RC118 for injection is a novel antibody-drug conjugate, with a Claudin 18.2-targeting antibody and a microtube inhibitor
Trial: NCT04980222
Drug: Glofitamab
RxNorm normalized name: Glofitamab
DrugBank: Glofitamab (DB16371)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive intravenous (IV) glofitamab as per schedule specified in the treatment arm.
Trial: NCT04980222
Drug: Tocilizumab
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive tocilizumab as needed to manage cytokine release syndrome (CRS).
Trial: NCT04980222
Drug: Vincristine
RxNorm normalized name: Vincristine
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive 1.4 mg/m2 body surface area of vincristine IV as per schedule specified in the treatment arm.
Trial: NCT04980222
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive 100 mg of prednisone or prednisolone as per schedule specified in the treatment arm.
Trial: NCT04980222
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive 375 mg/m2 body surface area of rituximab IV as per schedule specified in the treatment arm.
Trial: NCT05669313
Drug: Rivaroxaban 15 MG
RxNorm normalized name: rivaroxaban 15 MG
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rivaroxaban 15 mg after inclusion and on the morning after inclusion, i.e., before blood sampling
Trial: NCT05312255
Drug: Beta-Adrenergic Antagonist
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Receive beta-blocker regimen as per SOC
Trial: NCT05312255
Drug: Propranolol
RxNorm normalized name: Propranolol
DrugBank: Propranolol (DB00571)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT05064878
Drug: ZX008 (Fenfluramine Hydrochloride)
RxNorm normalized name: fenfluramine hydrochloride
DrugBank: Fenfluramine (DB00574)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZX008 is supplied as an oral aqueous solution of Fenfluramine Hydrochloride.
Trial: NCT05504239
Drug: Teneligliptin (as Teneligliptin Hydrobromide) 20 Mg Oral Tablet
RxNorm normalized name: Teneligliptin (as teneligliptin hydrobromide) 20 mg oral tablet
DrugBank: Teneligliptin (DB11950)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: To be orally administered once daily
Trial: NCT05504239
Drug: Teneligliptin Placebo Oral Tablet
RxNorm normalized name: placebo Oral Tablet
DrugBank: Teneligliptin (DB11950)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: To be orally administered once daily
Trial: NCT06210854
Drug: pBI-11
RxNorm normalized name: PBI-1402
DrugBank: PBI-1402 (DB05480)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HPV16/18 vaccine
Trial: NCT06698510
Drug: Arpraziquantel 150mg dispersible tablet
RxNorm normalized name: Disperse Blue 106
DrugBank: Praziquantel (DB01058)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Arpraziquantel 150mg dispersible tablets given as single oral dose of 50mg/kg (in Kenya and Uganda; for Schistosoma mansoni infection) or 60mg/kg (in Côte d'Ivoire; for mixed infections with S. mansoni / S. haematobium) using weight-based dosing tables as detailed in the summary of product characteristics.
Trial: NCT06146257
Drug: GLB-001
DrugBank: LB-001 (DB17685)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally according to the assigned treatment schedule
Trial: NCT06525155
Drug: Triptorelin Embonate
RxNorm normalized name: Triptorelin embonate
DrugBank: Triptorelin (DB06825)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment 1: 3.75 mg twice before surgery (baseline and week-6) and once after surgery at week-12
Trial: NCT06525155
Drug: Triptorelin Embonate
RxNorm normalized name: Triptorelin embonate
DrugBank: Triptorelin (DB06825)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment 2: 3.75 mg once after surgery at week-12
Trial: NCT05354674
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: AEM A：The specialist's decision to add bevacizumab to chemotherapy will be based on their own judgment~ARM B：The patient's PET/CT imaging, pathology, and clinical information were input into the signature, and the FOLFOX+Bevacizumab regimen was selected when the output label was 1. FOLFOXIRI chemotherapy regimen was selected when the output label was 0
Trial: NCT04711122
Drug: Third generation cephalosporin antibiotics
RxNorm normalized name: Cephalosporium roseum
DrugBank: Cephalosporium roseum (DB10932)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Assessment of antibiotic effect
Trial: NCT06136442
Drug: Atogepant
RxNorm normalized name: Atogepant
DrugBank: Atogepant (DB16098)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: atogepant in real life in Italy
Trial: NCT05269004
Drug: Ocrelizumab
RxNorm normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Ocrelizumab will be administered based on the dosage and administration received at the time of rollover from the Parent study.
Trial: NCT05950945
Drug: Trastuzumab Deruxtecan
RxNorm normalized name: Trastuzumab deruxtecan
DrugBank: Trastuzumab deruxtecan (DB14962)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous administration, 5.4 mg/kg on Day 1 of each 21-day cycle until radiographic disease progression as assessed by the investigator, unacceptable toxicity, other discontinuation criteria are met, or 2 years after first dose of study drug
Trial: NCT04764448
Drug: Belcesiran
RxNorm normalized name: Belcesiran
DrugBank: Belcesiran (DB18226)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered multiple fixed doses of belcesiran by subcutaneous (sc) injection for 24 weeks. Extension offered to participants.
Trial: NCT04764448
Drug: Belcesiran
RxNorm normalized name: Belcesiran
DrugBank: Belcesiran (DB18226)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered multiple fixed doses of belcesiran by subcutaneous (sc) injection for 48 weeks. Extension offered to participants.
Trial: NCT04764448
Drug: Belcesiran
RxNorm normalized name: Belcesiran
DrugBank: Belcesiran (DB18226)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered multiple fixed doses of belcesiran by subcutaneous (sc) injection for 96 weeks.
Trial: NCT05593575
Drug: SPH3127+SPH3127matching placebo+valsartan matching placebo
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 1 tablet of SPH3127 (50 mg) ，3 tablets of SPH3127 (50mg)matching placebo， 1 capsule of valsartan matching placebo, orally, once daily for 12 consecutive weeks
Trial: NCT05593575
Drug: SPH3127+SPH3127matching placebo+valsartan matching placebo
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 2 tablet of SPH3127 (50 mg) ，2 tablets of SPH3127 (50mg)matching placebo， 1 capsule of valsartan matching placebo, orally, once daily for 12 consecutive weeks
Trial: NCT05593575
Drug: SPH3127+valsartan matching placebo
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 4 tablet of SPH3127 (50 mg) ， 1 capsule of valsartan matching placebo, orally, once daily for 12 consecutive weeks
Trial: NCT05593575
Drug: SPH3127 matching placebo+valsartan
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 4 tablets of SPH3127 (50mg)matching placebo， 1 capsule of valsartan, orally, once daily for 12 consecutive weeks
Trial: NCT05873244
Drug: Zabadinostat (CXD101) and Geptanolimab
RxNorm normalized name: cytarabine and daunorubicin
DrugBank: Geptanolimab (DB16417)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Zabadinostat (CXD101) at 20mg twice daily per orally Day 1-5 every 3 weeks~* Geptanolimab at 3mg/kg given intravenously every 2 weeks
Trial: NCT05873244
Drug: Lenvatinib and Sorafenib
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clinicians' choice of TKI at corresponding recommended dosage:~* Lenvatinib at 8mg daily for patients with body weight \<60kg or 12mg daily with body weight ≥ 60kg~* Sorafenib at 400mg twice daily
Trial: NCT05306275
Drug: CSL312
RxNorm normalized name: Immunoglobulin G4, anti-(human blood-coagulation factor viia) (human monoclonal CSL312 gamma4-chain), disulfide with human monoclonal CSL312 lambda-chain, dimer
DrugBank: Garadacimab (DB15629)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Factor XIIa antagonist monoclonal antibody for subcutaneous use
Trial: NCT05358249
Drug: trametinib
RxNorm normalized name: Trametinib
DrugBank: Trametinib (DB08911)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: MEK inhibitor, oral
Trial: NCT05358249
Drug: Ribociclib
RxNorm normalized name: Ribociclib
DrugBank: Ribociclib (DB11730)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: CDK4/6 inhibitor, oral
Trial: NCT06492031
Drug: Icodextrin Peritoneal Dialysis Solution
RxNorm normalized name: Icodextrin Peritoneal Dialysis Solution
DrugBank: Icodextrin (DB00702)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The treatment modality, treatment frequency, treatment dose, duration of dwell, and length of treatment, as determined and supervised by a prescribing physician experienced in treating ESRD with PD.
Trial: NCT04727554
Drug: AMG 994
RxNorm normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as an intravenous (IV) infusion.
Trial: NCT04727554
Drug: AMG 404
RxNorm normalized name: Anti-pd-1 monoclonal antibody amg 404
DrugBank: AMG 424 (DB17357)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as an intravenous (IV) infusion.
Trial: NCT05144256
Drug: Mitapivat
RxNorm normalized name: Mitapivat
DrugBank: Mitapivat (DB16236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablets or granules
Trial: NCT05144256
Drug: Mitapivat-matching placebo
RxNorm normalized name: Mitapivat
DrugBank: Mitapivat (DB16236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablets or granules
Trial: NCT06166654
Drug: Acetazolamide
RxNorm normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1. 500 mg IV bolus of acetazolamide at randomization (day 0) and repeated the next 3 mornings (day 1, day 2 and day 3). This arm will also receive a placebo- Metolazone tablet together with each acetazolamide-injection.
Trial: NCT06166654
Drug: Metolazone 2.5 MG
RxNorm normalized name: metolazone 2.5 MG
DrugBank: Metolazone (DB00524)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2. 2.5 mg oral Metolazone at randomization (day 0) and repeated the next 3 mornings (day 1, day 2 and day 3). This arm will also receive a placebo- acetazolamide injection together with each metolazone-tablet.
Trial: NCT05458297
Drug: Nemtabrutinib
RxNorm normalized name: Nemtabrutinib
DrugBank: Nemtabrutinib (DB18866)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet
Trial: NCT06568939
Drug: Telisotuzumab Vedotin
RxNorm normalized name: Telisotuzumab vedotin
DrugBank: Telisotuzumab vedotin (DB15104)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) Infusion
Trial: NCT06165341
Drug: Fazirsiran Injection
RxNorm normalized name: Fazirsiran
DrugBank: Fazirsiran (DB17891)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fazirsiran will be injected subcutaneously.
Trial: NCT05767021
Drug: Mirikizumab
RxNorm normalized name: Mirikizumab
DrugBank: Mirikizumab (DB14910)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered IV
Trial: NCT05767021
Drug: Mirikizumab
RxNorm normalized name: Mirikizumab
DrugBank: Mirikizumab (DB14910)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT05446480
Drug: Desloratadine
RxNorm normalized name: Desloratadine
DrugBank: Desloratadine (DB00967)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ingestion 10mg pill 2 hours prior to heat strain trial. Second 10mg dose 24-hours later.
Trial: NCT05570994
Drug: 177Lu HTK03170
RxNorm normalized name: 177Lu-dotatate
DrugBank: Lutetium Lu 177 dotatate (DB13985)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive 177Lu HTK03170 treatment over 5 cycles, each cycle occurs every 8 weeks.
Trial: NCT05570994
Drug: 68Ga-HTK03149
RxNorm normalized name: 68Ga-DOTATOC
DrugBank: Dotatate gallium Ga-68 (DB13925)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 68Ga-HTK03149 PET/CT imaging; intravenous during screening
Trial: NCT06486662
Drug: OM-85-IN
RxNorm normalized name: Sudafed OM
DrugBank: Oxymetazoline (DB00935)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive a Single Ascending Dose (SAD): 1 day single dose treatment and Multiple Ascending Doses (MAD): 16 days multiple dose treatment of OM-85-IN
Trial: NCT05569382
Drug: Verapamil
RxNorm normalized name: Verapamil
DrugBank: Verapamil (DB00661)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1. week: uptitration with 120 mg capsules per day, until maximum dosage of 360 mg´s/day.~2-4. week: steady state treatment with the maximum tolerated dose.~5. week: downtitration
Trial: NCT05569382
Drug: Bisoprolol
RxNorm normalized name: Bisoprolol
DrugBank: Bisoprolol (DB00612)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1. week: uptitration with 2.5 mg capsules per day, until maximum dosage of 7.5 mg´s/day.~2-4. week: steady state treatment with the maximum tolerated dose.~5. week: downtitration
Trial: NCT04771520
Drug: Avapritinib
RxNorm normalized name: Avapritinib
DrugBank: Avapritinib (DB15233)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given PO
Trial: NCT06528496
Drug: Cytoxan
RxNorm normalized name: Cytoxan
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide is an alkylating agent related to nitrogen mustard
Trial: NCT06528496
Drug: Topotecan
RxNorm normalized name: Topotecan
DrugBank: Topotecan (DB01030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topotecan is a topoisomerase I-inhibitor that is a semisynthetic derivative of camptothecin.
Trial: NCT06528496
Drug: Vincristine
RxNorm normalized name: Vincristine
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vincristine is an alkaloid isolated from Vinca rosea Linn (periwinkle).
Trial: NCT06528496
Drug: Ifosfamide
RxNorm normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ifosfamide is a structural analogue of cyclophosphamide
Trial: NCT06528496
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Etoposide for Injection is available as a 20 mg/mL solution in sterile multiple dose vials (5 mL, 25 mL, or 50 mL each).
Trial: NCT06528496
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin is available in 50 mg, 150 mg, 450 mg, and 600 mg vials.